{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:Q89613",
      "entity_text" : "NS5A",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ04897",
      "entity_text" : "NS3/4A inhibitor",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "The fixed-dose, one-pill combination of grazoprevir (GZR), NS3/4A inhibitor, and elbasvir (EBR), which blocks the NS5A complex, was intended for GT1 and GT4 infected patients with standard therapy duration of 12 weeks, which assured an SVR rate over 95% [XREF_BIBR].",
  "reading_complete" : "2020-08-03T19:11:14Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T19:06:52Z",
  "trigger" : "blocks",
  "evidence" : [ "NS3/4A inhibitor, and elbasvir (EBR), which blocks the NS5A" ],
  "pmc_id" : "6935848",
  "score" : 0
}